In addition to being important for normal fetal and postnatal growth, there is increasing evidence that insulin-like growth factors I and II (IGF-I, IGF-II) also support the growth of certain cancers. Biologic responses to IGF-I and IGF-II are signaled by the IGF-I receptor. Therefore, we are focusing our research effort on understanding signaling by the IGF-I receptor. We have used the yeast two-hybrid system to identify new binding partners for the IGF-I receptor. We have inserted the cytoplasmic domain of the IGF-I receptor into the LexA DNA binding vector. Poly A mRNA was prepared from the human osteosarcoma cell line, MG-63, and given to a commercial laboratory for preparation of a cDNA library in the yeast two-hybrid activation domain vector. The library screen identified IGF-I receptor binding partners that we and others had previously identified (p85 regulatory subunit of PI3-K, p66 Shc, Grb10, 14-3-3 beta and zeta, SOCS-1, SH2-B/PSM, RACK-1) as well as new interactors (STAT5a, GIPC, Ril, and 4 clones that are not fully characterized). We are focusing on GIPC which represented 25% of the most strongly interacting clones. GIPC did not interact with the insulin receptor in the yeast two hybrid assay. GIPC is a 333 amino acid protein with a central SH2 domain. Mutational analysis in the yeast two-hybrid system showed that GIPC PDZ domain binds to the carboxy tail of the IGF-I receptor. GIPC dimerizes and the dimerization domain has been shown to include the amino terminal domain as well as a portion of the PDZ domain. IGF-I receptor constructs that have been mutated to prevent GIPC binding have been transfected into IGF-I receptor null mouse embryo fibroblasts in order to explore the function of GIPC in IGF-I receptor signaling. We have developed a mouse monoclonal antibody (4G11) directed against the human IGF-I receptor. This monoclonal antibody blocks the binding of radiolabeled IGF-I to MCF-7 breast cancer cells and MG-63 osteosarcoma cells and downregulates the receptor.

Agency
National Institute of Health (NIH)
Institute
Division of Clinical Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC004016-29
Application #
6756196
Study Section
Metabolism Study Section (MET)
Project Start
Project End
Budget Start
Budget End
Support Year
29
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code